《金融时报》周五援引知情人士消息报道，史赛克（SN.L）与强生（JNJ.N）就合并后者骨科部门的谈判破裂，原因是这家伦敦上市公司拒绝同意由其前任CEO领导合并后的企业。
Smith & Nephew's (SN.L) talks with Johnson & Johnson (JNJ.N) to combine with the US group’s orthopaedics division fell apart after the London-listed group refused to agree to its former CEO leading the merged business, the Financial Times reported on Friday, citing people familiar with the matter.
报道称，史赛克与强生骨科部门的合并谈判已处于高级阶段，双方在交易的主要财务条款和架构上达成一致，但在最后一刻因谁将掌管合并后的大公司产生分歧而告吹。
Talks about a merger between Smith & Nephew and the J&J unit were at an advanced stage, with both companies aligned on the main financial terms and structure of a transaction, but collapsed at the last minute after disagreement over who would run the enlarged company, the report said.
据《金融时报》报道，史赛克前任CEO纳马尔·纳瓦纳于2019年离职，此前他在该职位上任职18个月，因这家英国医疗器械公司无法满足其薪酬要求。
Smith & Nephew's former CEO Namal Nawana left in 2019 after 18 months in the role because the UK medical devices company could not meet his pay demands, the FT report said.
报道补充称，史赛克拒绝了该交易，表示只有在其现任掌门人迪帕克·纳特继续担任CEO的情况下才会同意。
Smith & Nephew refused the deal, saying it would only agree if its own boss Deepak Nath remained CEO, the report added.
史赛克发言人拒绝就该报道置评。强生在非工作时间无法立即联系到。
A Smith & Nephew spokesperson declined to comment on the report. J&J could not be immediately reached outside of business hours.
报道称，拟议交易将强生的髋关节和膝关节置换部门估值高达220亿美元，几乎是史赛克94亿英镑（约125.8亿美元）市值的两倍。
The proposed deal would have valued J&J's hip and knee replacement unit at as much as $22 billion, almost double Smith & Nephew’s £9.4 billion ($12.58 billion) market capitalisation, the report said.
强生于2025年10月宣布计划将其骨科业务分拆为一家名为DePuy Synthes的独立公司。据报道，该部门寻求200亿美元的价格，此后吸引了私募股权基金的兴趣，但迄今尚未达成交易。
J&J announced plans to separate its orthopaedics business into a standalone company named DePuy Synthes in October 2025. The unit, which was reportedly seeking a $20 billion price tag, has since drawn private equity interest, but no deal has materialised yet.